Evidence map›Paper›PMID 29895187›Full record

Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018

Factor VIII in Acute Cerebral Ischemia Pilot Study: Biomarker in Patients With Large Vessel Occlusion?

Digvijaya Navalkele, Amelia Boehme, Karen Albright, Cindy Leissinger, Laurie Schluter, Melissa Freeman, Stacy Drury, Ramy El Khoury, T Mark Beasley, Sheryl Martin-Schild

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Coagulation biomarkers for ischemic stroke.Research and practice in thrombosis and haemostasis · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Digvijaya Navalkele1 Touro Infirmary and New Orleans East Hospital, New Orleans, LA, USA.
Amelia Boehme2 Department of Neurology, Columbia University, New York, NY, USA.
Karen Albright3 Department of Neurology, The State University of New York, New York, NY, USA.
Cindy Leissinger4 Tulane University, New Orleans, LA, USA.
Laurie Schluter1 Touro Infirmary and New Orleans East Hospital, New Orleans, LA, USA.
Melissa Freeman5 Touro Infirmary, New Orleans, LA, USA.
Stacy Drury4 Tulane University, New Orleans, LA, USA.
Ramy El Khoury1 Touro Infirmary and New Orleans East Hospital, New Orleans, LA, USA.
T Mark Beasley6 University of Alabama in Birmingham, Birmingham, AL, USA.
Sheryl Martin-Schild1 Touro Infirmary and New Orleans East Hospital, New Orleans, LA, USA.

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

We conducted a prospective serial laboratory cohort study to assess the correlation of factor VIII (FVIII) levels in response to thrombolysis in patients with large vessel occlusion (LVO) and acute ischemic stroke (AIS). Patients with AIS with anterior circulation LVO were eligible for enrollment if treated within 4.5 hours from last seen normal with intravenous tissue plasminogen activator (tPA). Patients (n = 29) had a mean age of 71 years and median National Institute of Health Stroke Scale of 14. Baseline pre-tPA FVIII was not significantly correlated with clot burden score (-0.147, P = .447) or vessel recanalization (-0.133, P = .499). Median FVIII decreased significantly from baseline to 6 hours post-tPA (282% to 161%, P = .002), but delta in FVIII level did not correlate with vessel recanalization (0.013, P = .948). There was no difference between median FVIII level at baseline and 90 days post-AIS. FVIII level decreased significantly after tPA, but baseline FVIII level and early change in FVIII level were not significant predictors of clot burden, vessel recanalization after thrombolysis, or symptomatic hemorrhage.

Indexed as

Brain IschemiaStrokeThrombolytic TherapyThrombosisAgedAged, 80 and overBiomarkersFactor VIIIFemaleHumansMaleMiddle AgedPilot ProjectsProspective StudiesTime FactorsTissue Plasminogen ActivatorBiomarkersF8 protein, humanFactor VIIITissue Plasminogen Activatorbiomarkersfactor VIIIpilot studystroke

Identifiers

PMID29895187
PMCPMC6714777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.